DK0538341T3 - EHV-4-gycoproteinvaccine. - Google Patents

EHV-4-gycoproteinvaccine.

Info

Publication number
DK0538341T3
DK0538341T3 DK91912865.2T DK91912865T DK0538341T3 DK 0538341 T3 DK0538341 T3 DK 0538341T3 DK 91912865 T DK91912865 T DK 91912865T DK 0538341 T3 DK0538341 T3 DK 0538341T3
Authority
DK
Denmark
Prior art keywords
ehv
gycoproteinvaccine
polypeptides
fragments
presented
Prior art date
Application number
DK91912865.2T
Other languages
Danish (da)
English (en)
Inventor
Lesley Nicolson
David Edward Onions
Original Assignee
Univ Glasgow
Equine Virology Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow, Equine Virology Res Found filed Critical Univ Glasgow
Application granted granted Critical
Publication of DK0538341T3 publication Critical patent/DK0538341T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK91912865.2T 1990-07-06 1991-07-04 EHV-4-gycoproteinvaccine. DK0538341T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909014950A GB9014950D0 (en) 1990-07-06 1990-07-06 Ehv-4 glycoprotein vaccine

Publications (1)

Publication Number Publication Date
DK0538341T3 true DK0538341T3 (da) 1997-06-30

Family

ID=10678729

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91912865.2T DK0538341T3 (da) 1990-07-06 1991-07-04 EHV-4-gycoproteinvaccine.

Country Status (15)

Country Link
US (1) US6083511A (ja)
EP (1) EP0538341B1 (ja)
JP (1) JPH05509226A (ja)
AT (1) ATE147100T1 (ja)
AU (1) AU8200791A (ja)
CA (1) CA2086739A1 (ja)
DE (1) DE69123970T2 (ja)
DK (1) DK0538341T3 (ja)
ES (1) ES2099164T3 (ja)
GB (1) GB9014950D0 (ja)
GR (1) GR3023297T3 (ja)
HU (1) HU217211B (ja)
NZ (1) NZ238833A (ja)
WO (1) WO1992001057A1 (ja)
ZA (1) ZA915230B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
ATE259417T1 (de) * 1992-06-01 2004-02-15 Univ Melbourne Immunologisches verfahren für die detektion von pferde-herpesvirus typ 1 und 4 glycoprotein g antikörper
US6225111B1 (en) 1992-08-07 2001-05-01 Schering Plough Veterinary Corp. Recombinant equine herpesviruses
NZ265114A (en) * 1993-04-14 1996-10-28 Re Mark It Holdings Ltd Erasible sign formed by upper sheet releasably adhering to base layer to make indicia more visible or less visible
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
AR040601A1 (es) * 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
US7323178B1 (en) 2004-01-16 2008-01-29 The Ohio Department Of Agriculture Method of identification of equine herpes virus type 1 causing neurological disease, method of producing a vaccine against neurological disease caused by equine herpes virus type 1, and vaccine against neurological disease caused by equine herpes virus type 1
EP2163634A1 (en) 2004-12-08 2010-03-17 SunGene GmbH Expression cassettes for vascular tissue-preferential expression in plants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
WO1990001546A1 (en) * 1988-08-05 1990-02-22 Applied Biotechnology, Inc. Equine herpesvirus-1 vaccine

Also Published As

Publication number Publication date
HU9300009D0 (en) 1993-04-28
GR3023297T3 (en) 1997-07-30
GB9014950D0 (en) 1990-08-29
EP0538341B1 (en) 1997-01-02
HU217211B (hu) 1999-12-28
HUT69920A (en) 1995-09-28
ZA915230B (en) 1992-04-29
WO1992001057A1 (en) 1992-01-23
US6083511A (en) 2000-07-04
EP0538341A1 (en) 1993-04-28
DE69123970D1 (de) 1997-02-13
CA2086739A1 (en) 1992-01-07
ATE147100T1 (de) 1997-01-15
NZ238833A (en) 1993-02-25
ES2099164T3 (es) 1997-05-16
JPH05509226A (ja) 1993-12-22
AU8200791A (en) 1992-02-04
DE69123970T2 (de) 1997-07-24

Similar Documents

Publication Publication Date Title
NO964862L (no) Papillomavirusvaksiner
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
HU9501288D0 (en) Recombinant method and host for manufacture of xylitol
ATE38036T1 (de) Benzothiophenderivate als bronchodilatoren.
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
IT1271486B (it) Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
DE3853743D1 (de) Rekombinanter menschlicher ADF.
IT1238202B (it) Proiettore ad inclinazione regolabile.
IT8920839A0 (it) Procedimento e dispositivo per la realizzazione di pannelli.
DE69122612D1 (de) Interleukin-4-bindeprotein-gamma
DE69130953D1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
DK0511516T3 (da) Schizosaccharomyces-specifikke polypeptider
IT8125642A0 (it) Procedimento per la duplicazione di sagome e finiture.
ITRM920517A1 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.
NO893458L (no) Fremgangsmaate og kakalysator for fremstilling av syntesegass.
IT216579Z2 (it) Dispositivo macinatore per pepe e simili.
FI914334A0 (fi) Dihydropyrimidin antiallergiska aemnen.